(Q37797795)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

3

Dominick J Angiolillo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Ángel R Cequier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

4 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

Diabetes and Vascular Disease Research

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

274-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

Global and societal implications of the diabetes epidemic

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Pathobiology and cell interactions of platelets in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin for primary prevention of cardiovascular events in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet inhibition by insulin is absent in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

TP receptor antagonism: a new concept in atherothrombosis and stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Clinical overview of promising nonthienopyridine antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Cangrelor: a review on its mechanism of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Coronary stent restenosis in patients treated with cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting St

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Mechanism of action and clinical development of platelet thrombin receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

New oral anticoagulants: a practical guide for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164110383995

21 January 2018

Identifiers

DOI

10.1177/1479164110383995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference